Medy Tox Inc operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Medy Tox Inc with three other
companies in this sector in South Korea:
sales of 182.09 billion Korean Won [US$161.69 million]
Komipharm International Company Limited
(36.64 billion Korean Won [US$32.54 million]
of which 100%
was Animal Pharmaceutical), and
Cell Biotech Co ., Limited.
(61.06 billion Korean Won [US$54.22 million]
of which 88%
was Finished Products).
During the year ended December of 2017, sales at
Medy Tox Inc were 181.24 billion Korean Won (US$160.94 million).
increase of 36.0%
versus 2016, when the company's sales were 133.26 billion Korean Won.
This was the fifth consecutive year of sales increases at Medy Tox Inc
(and since 2012, sales have increased a total of 400%).